An interventional study of Radiotherapy and MRI in Brain Tumours and Proton Therapy, sponsored by Universitaire Ziekenhuizen KU Leuven. Not yet recruiting at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Brain Neoplasms with a site in Belgium — 16 open to participants now, 22 under way, 4 of them phase 3. Brain Neoplasms · Belgium.
Among the 59 studies in Brain Neoplasms with a site in Belgium, this one is the 28th largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2027, is one of 9 with no phase, reaches primary completion later than 16 of the 21 other live ones, and was the 58th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →16 of the 59 studies in Brain Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Belgium, United States, Canada and 10 more countries
Ages 18+
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 18+
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Belgium, Australia, Austria and 1 more country
Ages 18+
Erasme University Hospital · Sites in Belgium
Ages 18–90
Algemeen Ziekenhuis Maria Middelares · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 22 · Phase 3 16
First in 1996; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 153 across the 46 interventional studies, 170 across the 12 observational. Of the 34 that completed or were terminated, 13 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 964 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 6 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Brain Neoplasms with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT06273176Erasmus Medical CenterThe RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma | 2027-01-01 |
| NCT06118723Jasper GerritsenThe SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) | 2027-01-01 |
| NCT06835426Algemeen Ziekenhuis Maria MiddelaresHigh-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins | 2027-01-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 59 studies in Brain Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.
In clinical treatment planning, a constant RBE of 1.1 is assumed. However, proton RBE depends on several factors, including linear energy transfer (LET). RBE uncertainties can result in unexpected toxicities in patients treated with proton therapy (PT) for primary brain tumours. To address RBE uncertainties in PT treatment planning, this prospective trial evaluates the feasibility and outcomes of incorporating LET distribution information and the McNamara variable RBE model into treatment planning for patients diagnosed with primary brain tumours. The primary objective is to evaluate the effect of this planning strategy on the incidence of treatment-related imaging abnormalities (TRIA) in healthy brain tissue after PT. Outcomes will be compared with those of a historical cohort of patients who received PT at the same centre before the introduction of the novel planning strategy.
Secondary objectives are:
Participants will undergo standard clinical and MRI follow-up and will complete quality-of-life questionnaires at predefined time points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed with primary brain tumours including, but not limited to:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: Radiotherapy · Diagnostic Test: MRI · Other: Quality of Life (QoL) assessments. · Other: Toxicity scoring
Treatment planning will initially be performed according to standard clinical practice using an RBE-weighted dose based on a fixed RBE of 1.1, expressed in Gy(RBE). The resulting plan will then undergo additional evaluation using LET distributions and variable RBE-weighted dose distributions calculated with the McNamara model. If areas of high LET or high estimated biological dose are identified in healthy brain tissue, the treatment plan may be adjusted to reduce these areas while maintaining adequate target coverage and compliance with standard dose constraints for organs at risk. LET and variable RBE evaluation will be used as auxiliary planning metrics and will not replace standard clinical dose evaluation.
Also known as: Proton therapy, LET-based treatment evaluation, LET-based treatment planning, variable RBE-based treatment evaluation, variable RBE-based treatment planning
MRI assessments according to routine follow-up for TRIA and response assessment.
Assessing QoL in adults (aged \> 25 years) using the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumour Module.
Evaluating the incidence of CNS toxicities using the CTCAE v5.0
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
TRIA is defined as any new or increased abnormality observed on post-contrast T1-weighted, T2-weighted, or T2-weighted-FLAIR MRI sequences, absent on the corresponding pre-radiotherapy (and post-surgical, if surgery preceded radiotherapy) imaging, not consistent with post-surgical changes or unambiguous tumour progression, with confirmation on subsequent follow-up MRI recommended to substantiate this diagnosis. TRIA will be scored as a CNS necrosis adverse event according to the CTCAE scale version 5.0.
Time frame: Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
Treatment planning feasibility: number of plan iterations.
Evaluating the number of plan iterations required for a satisfactory LET-based treatment plan, acting as a surrogate for additional planning time required in the treatment planning workflow.
Time frame: Baseline (during treatment planning).
Treatment planning feasibility: number of plans requiring LET-based replanning.
Evaluating the number of RBE1.1-based plans in need of a replanning to a LET-based treatment plan.
Time frame: Baseline (during treatment planning).
Treatment planning feasibility: planning effort
Evaluating the effort needed for replanning using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Workload is rated on six subscales (mental demand, physical demand, temporal demand, performance, effort and frustration), each scored from 0 to 20; the overall score is the mean of the six subscales (0-20). Higher scores indicate a higher workload (worse outcome).
Time frame: Baseline (once before and once after LET-based replanning).
CNS toxicities
Evaluating the incidence of CNS toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death related to adverse event); higher grades indicate a worse outcome.
Time frame: Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
Assessing QoL in adults (aged \> 25 years) using the EORTC QLQ-C30. Scores range from 0 to 100. For the global health status and functional scales, higher scores indicate better quality of life and functioning; for the symptom scales, higher scores indicate a higher symptom burden (worse outcome).
Time frame: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
Assessing QoL in adults (aged \>25 years) using the EORTC QLQ-BN20. Scores range from 0 to 100; higher scores indicate a higher symptom burden (worse outcome).
Time frame: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumor Module. Scores range from 0 to 100; higher scores indicate better health-related quality of life.
Time frame: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
Response assessment
Number of participants per response category (complete response, partial response, stable disease, progressive disease) according to the Response Assessment in Neuro-Oncology (RANO) criteria.
Time frame: At 6 and 12 months after proton therapy.
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
Comparing the maximum dose-averaged linear energy transfer (LETd), reported as D1% (in keV/µm), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.
Time frame: Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
Comparing the maximum constant RBE-weighted dose (RBE 1.1), reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.
Time frame: Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
Comparing the maximum McNamara variable RBE-weighted dose, reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan.
Time frame: Baseline (after treatment planning).
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
Comparing target coverage, reported as \[CTV D98%\] (in Gy(RBE)), between the RBE1.1-based plan and the LET-based plan.
Time frame: Baseline (after treatment planning).
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Apr 2028, 15 months later.
Of 306 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 15 months is below that.
Counting every sponsor, half of 317 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →